Uniting Leading Drug Developers & Academics to Successfully Deliver siRNA into Extrahepatic Tissues
Building on the success of the 2022 summit, we bought the RNAi-Based Therapeutics Summit back with a refreshed agenda, and brand new content, and showcased new companies that haven’t presented at this meeting in the past.
In March 2023, the 4th RNAi-Based Therapeutics Summit returned to Boston to welcoming 90+ technical and strategic expertise from Early Discovery, Preclinical, Clinical, Delivery, and Manufacturing to learn and network with pioneers in the space to turbocharge more RNAi therapies into the clinic and into extra-hepatic tissues.
With a brand new pre-conference focus day on evaluating next-generation delivery technologies, the summit offered the full end-to-end of RNAi drug development to support your own journey to fully realize the potential of siRNA.
With 20+ pioneering speakers from large pharma, innovative biotech, and KOLs of academia, the 2023 summit discussed novel delivery modalities, next-generation chemistries, clinical updates scaling up and more.
Join the ever-growing audience of RNAi experts in 2024 seeking to overcome the challenges of developing RNAi therapies that overcome barriers to extra-hepatic delivery to the CNS and beyond, improve selectivity, and fast-track candidates into, and through the clinic towards approval.
Here is a snapshot of our 2023 expert speakers:
Vice President, Senior Director & Head of Chemistry, Manufacturing & Controls
Dicerna TRU of Novo Nordisk